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Throughout life, bone tissue undergoes a continuous process of resorption and formation. Melatonin, with its antioxidant
properties and its ability to detoxify free radicals, as suggested by Conconi et al. (2000) may interfere in the osteoclast function
and thereby inhibit bone resorption, as suggested by Schroeder et al. (1981). Inhibition of bone resorption may be enhanced by a
reaction of indoleamine in osteoclastogenesis. That it has been observed melatonin, at pharmacological doses, decrease bone mass
resorption by suppressing through down regulation of the RANK-L, as suggested by Penarrocha Diago et al. (2005) and Steflik
et al. (1994). These data point an osteogenic eﬀect towards that may be of melatonin of clinical importance, as it could be used
as a therapeutic agent in situations in which would be advantageous bone formation, such as in the treatment of fractures or
osteoporosis or their use as, a bioactive surface on implant as suggested by Lissoni et al. (1991).
1. Introduction
The bone tissue is a variety of connective tissues that are
essentially a mineralized extracellular matrix and specialized
cells: osteoblasts, osteocytes, and osteoclasts.
The organic component, or osteoid matrix produced
by osteoblasts, is constituted by 90% of type I collagen
fibers, which represents the major structural protein of bone
matrix. The remaining 10% is made up of a series of non-col-
lagenous proteins that modulate smaller mineralization and
binding of cells to the matrix, and among them (see Table 1).
The inorganic phase consists of small crystals of a min-
eral alkaline character, hydroxyapatite [Ca10(PO4)6(OH)2].
These crystals are embedded among the collagen fibers to
form a fabric that meets the appropriate characteristics of
rigidity, flexibility, and endurance [1–3].
Osteoblasts derived embryologically multipotent pro-
genitor cells from bone marrow stroma. These cells origi-
nate from osteoblasts, as well as fibroblasts, chondrocytes,
adipocytes, and muscle cells, some of which are phenotypic
characteristics similar to those of osteoblast. These cells are
metabolically active secretory proteins expressed as osteo-
calcin and osteopontin, osteonectin and other proteoglycans
and soluble markers factors (BMPs, TGF-β, IGF I and II, IL-1
and PDGF). The expression of these products by osteoblasts
bone occurs during embryogenesis, and during maintenance
(remodeling), and repair. The signals that direct osteoid
mineralization have not yet been identified. It is likely that
the accumulation of proteins in a calcium will be the begin-
ning of the process of mineralization [4].
Although osteoblasts are polarized towards the bone, the
release of the osteoid matrix proteins is not limited to the
basal pole, but many of them are being involved in such
a matrix, becoming osteocytes included in the gaps that form
in it.
Osteoblasts can lead to surface osteocytes, also known as
lining cells. Both types of bone cells possess receptors for
parathyroid hormone (PTH) and express mRNA Live: β-
actin, transcription factors c-fos and c-jun proteins collagen
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Table 1: Osteoid matrix proteins.
(1) Collagen type I (90%)
(2) Noncollagenous proteins (10%)
(i) Glycoproteins:
(a) Alkaline phosphatase
(b) RGD sequence-glycoproteins (osteopontin, osteonectin, fibronectin, thrombospondin, and bony sialoprotein)
(ii) Proteoglycans
(iii) Proteins with γ-carboxyglutamic acid (osteocalcin, osteoid protein γ-carboxyglutamic acid)
(iv) Serum proteins retained in the bone
and collagen as well as mRNA-like growth factor insulin I
(IGF-I) [5].
Already formed in the bone, the osteocytes included in
the gaps or osteoplasmas in the mineralized matrix, are star-
shaped with numerous thin extensions, and are connected by
a network of canals or ducts calcoforos, bathed by the so-
called bone fluid. Such networks of channels are formed
before they mineralize the osteoid matrix.
When there is bone resorption by osteoclasts, osteocytes
are out of the lagoons as cladding in repose cells [3]. Bone
resorption is a complex process involving the dissolution of
the mineral or inorganic phase and subsequent degradation
of bone matrix proteins. Osteoclasts adhere to the bone
surface via integrins that specifically recognize osteoidmatrix
proteins. The sealing area delimits a microgap between
osteoclasts and bone surface. Demineralization is produced
by acidification of the microgap by the action of Hydrogen
(H+) ATPase located in the brush border membrane. To
maintain the physiological pH within it, the osteoclast has
a heat exchanger (Cl−/HCO3−) on the opposite side of the
brush border and, on this edge, a channel Chlorine (Cl−)
coupled H+-ATPase. As a consequence the osteoblast secretes
HCl in the microsubosteoclastic, thus lowering the pH to 4.4
and the dissolution of the mineral. This dissolution precedes
the organicmatrix degradation, carried out by proteases such
as cathepsin K, secreted by osteoclasts, and collagenase by
osteoblasts [6, 7].
2. Bone Remodeling
Throughout life, bone tissue undergoes a continuous process
of resorption and formation. By continuing, there are areas
of bone which are destroyed to be replaced by newly formed
bone tissue. This process is called “bone remodeling” and
leads to the replacement of about 7–10% of the total volume
of the skeleton each year.
The remodeling is done by groups of cells, osteoblasts
and osteoclasts that are called “units of remodeling” or “basic
multicellular units.” The process begins when osteoclast
precursors are attracted to a particular location of the bone,
and the action of cytokines (TNF-α, IL-1, IL-6, M-CSF,
RANK-L) diﬀerentiates osteoclasts in situ. These begin to
reabsorb bone, along untill two weeks later a small cavity
is lined by mononuclear cells called the investment phase.
After osteoblast precursors are recruited to proliferate and
diﬀerentiate osteoblasts are arranged in a monolayer to
synthesize osteoid filling while the gap is opened by the
osteoclasts. It is the bone formation phase, which lasts for
2–4 months. The mineralization of sheets of osteoid is being
produced as deposited, but with a delay of 2 weeks. At the
end of the process, the result is that a small amount of old
bone by new bone renovated [8] (see Table 2).
Numerous studies documented that melatonin is an
important mediator in bone formation and stimulation [9].
At micromolar concentrations, melatonin synthesis stimu-
lates the proliferation and collagen fibers of type I in human
osteoblasts in vitro [10].
The eﬀect of pineal gland/melatonin (aMT) upon circa-
dian secretion of hormones, especially those playing a crucial
role in the regulation of bone metabolism appears significant
[11, 12]. Early experimental studies conditions have shown
that long-term light,and pinealectomy also modified the
synthesis aMT administration and/or circadian release of
growth hormone (GH), insulin-like growth factor-I (IGF-I)
as well as calciotropic, thyroid, adrenal cortex hormones and
testes. Also enhances synthesis of aMT and noncollagenic
proteins of bone matrix [10]. That characteristic suggests
that clinical studies of bone mass changes in postmenopausal
osteoporosis may be related to aMT [13]. Studies demon-
strate that increased obese women aMT secretion in more
than 20% overweight have protective significance in loss of
bone mass aftermenopause [14].
Melatonin is not a hormone in the classic sense, but as a
cell protective functions and an antioxidant [15]. It is known
that the enzymes required for the biosynthesis of melatonin
are found in tissues other than the pineal gland, and it is
also known that several of these tissues, amongst them the
retina, thymus, spleen, B-lymphocytes, ovaries, testicles, and
the intestine, all produce melatonin. Extrapineal melatonin
is produced by specific organs used locally as paracoid or
autocoid and does not enter the circulation [16]. Melatonin
does not act upon specific target organ and stock. It
reaches all tissues and due to amphiphilicity, it enters to
all subcellular compartments [17, 18]. Moreover, several
organelles and the nucleus including the mitochondria may
accumulate melatonin [18, 19].
Melatonin, with its antioxidant properties and its ability
to detoxify free radicals [20] in this may interference of the
osteoclast function and thereby inhibit bone resorption [21].
Inhibition of bone resorption may be enhanced by a reaction
of indoleamine in osteoclastogenesis. It has been observed
that melatonin, at pharmacological doses, increases bone
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Table 2: Regulatory factors of bone modeling.
(i) Hormones
(a) Parathyroid hormone (PTH)
(b) 1, 25 (OH)2 vitamin D
(c) Calcitonin
(d) Glucocorticoids
(e) Growth hormone
(f) Sex hormones (estrogens and androgens)
(ii) Local factors (paracrine and autocrine)
(a) Growth factors and cytokines
(iii) Other molecules
(a) Prostaglandins, leukotrienes, extracellular ATP, Bradykinin, CGRP
mass by supressing resorption trough down-regulation of
the RANKL-mediated osteoclast formation and activation.
These data point an osteogenic eﬀect towards that may be
of melatonin of clinical importance, as it could be used as
a therapeutic agent in situations in which there would be
advantageous bone formation, such as in the treatment of
fractures or osteoporosis [21].
Links between melatonin metabolism and bone have
been documented in many studies [10, 21, 22]. Investiga-
tions, acted melatonin on the bone as a local growth factor,
with paracrine eﬀects on nearby cells [23, 24].
3. Osseointegration in Oral Implantology
Osseointegration requires the formation of new bone around
the implant, resulting in the remodeling process within the
bone tissue. The process was initiated by osteoclasts, which
are the cells responsible for reabsorbing the necrotic area
originated by bone drilling during the preparation of the
recipient bone. With them, vascular neoformation provide
the cells elements, the osteoblasts, which create new bone
able to interact with the titanium oxide layer of the
implant to integrate biologically to it. Osteoblasts are dif-
ferentiated osteocytes subsequently included in the min-
eralized bone matrix. Considering ultrastructurally bone-
implant interface must refer to the concept of biointegration,
which is the direct biochemical joint between the bone
and the implant surface, demonstrable through electronic
microscopy, regardless any interunion mechanism. Thus, the
space between the mineralized bone tissue and titanium
plasma coating of the implant is not more than 10 Angstrom
and appears filled with a matrix material, the proteoglycans
[25]. A network of collagen is surrounding the osteocytes and
inserted into the layer of glycoproteins, which fusions with
titanium oxide layer. It is believed that the implant titanium
oxide induces the formation of sulfated glycosaminoglycans
[26]. The bony trabeculae grow closer to the implant contact-
ing the plasma layer. From them come the vessels supplying
nutrition, cellular elements for remodeling and around
the implant, fibroblasts, and osteoblasts to increase and
approach the implant which is attached to the oxide layer.
They are fundamental substances that fills the trabecular
spaces and fuse with the titanium oxide layer. Therefore, and
contrary to what is believed, the oral tissue-implant interface
is a dynamic area under intense remodeling activity by the
bone cells and the extracellular matrix [27].
4. Melatonin and Cancer
Melatonin can kill directly many diﬀerent types of human
tumor cells [28, 29]. It is a naturally produced cytotoxin,
which can induce tumor cell death (apoptosis) [30, 31]. In
instances where the tumor has already established itself in
the body, melatonin has been shown to inhibit the tumor’s
growth rate [32, 33]. Melatonin exhibits natural oncostatic
activity and inhibits cancer cell growth [34]. In patients
in whom cancer already has become a noticeable physical
burden which produces overt symptoms, melatonin has
been shown to alleviate numerous cancer symptoms [35]
and to inhibit development of new tumor blood vessels
(tumor angiogenesis) [36], which in turn inhibits the cancer
from spreading further (metastasis) [37]. Melatonin can
retard tumor metabolism and development by lowering the
body temperature; it is a natural inducer of hypothermia.
Furthermore, as an inducer of antioxidants [38], and itself a
weak preventive antioxidant, melatonin hinders tumor cells
from participating in free radical damage to normal cells and
consequently limits oxidative damage to DNA, lipids, amino
acids, and proteins. Melatonin promotes bone formation
[39] and on the other hand with its antioxidant action on
free radicals interferes with the osteoclast and thus inhibits
bone resorption [40, 41].
5. Conclusion
Although today the designs and surface treatment of im-
plants are allowing in some cases reduce load times, generally
provides a period of osseointegration in the mandible 3
months and 6 months in the maxilla.Cutando et al. [42]
found that at 2 weeks of melatonin implants significantly
increased all parameters of osseointegration of them: per-
centage of bone contact, total peri-implant bone, bone inter-
screw, and the percentage of new bone formation. Roth
et al looked melatonin stimulated, the expression of bone,
sialoprotein genes, alkaline phosphatase and osteocalcin for a
period of time from 5 to 9 days, founding a highly significant
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evidence for this relationship because the genes of many
of the bone matrix proteins (BSP, ALP, OC, and SPARC)
contain the sequence of bases (RGGTCA) required for
nuclear receptor binding of melatoninRZR to its promoter
region. However, this increase in bone tissue formation may
also be mediated by membrane receptors of the indoleamine,
and that treatment with pertussis toxin and luzindole is able
to reduce the expression of BSP and ALP [43].
All these data confirm that an osteogenic eﬀect of
melatoninmay be clinically important as it could be used as a
potential therapeutic agent in situations where it is desirable
to increase bone formation and healing of fractures or
osteoporosis, or their use as a bioactive surface on implant
[44].
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